The core of the argument is deceptively simple. A platelet count tells you how many platelets are circulating, but says nothing about whether they work. Platelets contribute to hemostasis through adhesion, activation, granule release, aggregation, and support of thrombin generation, and none of these functions is captured by a routine count. Multiple studies have now documented profound platelet dysfunction in patients with traumatic brain injury even when their counts sit comfortably within the normal range. The authors define this dysfunction as a measurable impairment in agonist-induced aggregation, in the responsiveness of specific receptor pathways, or in the platelet’s contribution to whole-blood clot strength, occurring disproportionately to or entirely in the absence of thrombocytopenia. In other words, a patient can have plenty of platelets and still have platelets that fail.

The biological explanation lies in the unique nature of brain injury. When neural tissue is disrupted, it releases tissue factor, damage-associated molecular patterns, microparticles, and lipid mediators into the circulation, triggering thrombin generation, platelet activation, and ultimately receptor desensitization. The result is a paradoxical hemostatic state the authors describe as activation exhaustion: early procoagulant activation coexists with downstream hyporesponsiveness. Platelet activation and platelet dysfunction, far from being mutually exclusive, appear to be overlapping temporal phases of the same post-injury response. This may explain a frustrating clinical pattern in which patients with traumatic brain injury suffer early hemorrhagic progression of their intracranial lesions and later develop thrombotic complications, two seemingly opposite outcomes arising from the same underlying biology.

The strongest mechanistic evidence comes from a study by Castellino and colleagues, who examined 70 patients with isolated head injury, carefully excluding hemorrhagic shock, hypotension, and antiplatelet medication use. In severe traumatic brain injury, they found adenosine diphosphate, or ADP, pathway inhibition of 93.1 percent, with an interquartile range of 44.8 to 98.3 percent, compared with just 15.5 percent in controls, a difference that was highly statistically significant, and the arachidonic acid pathway was involved concurrently. A parallel rat model confirmed ADP inhibition of 77.6 percent, plus or minus 6.7 percent, just 15 minutes after injury. These findings establish that brain injury alone, independent of systemic hemodynamic compromise, generates profound receptor-level platelet dysfunction, a mechanism distinct from pharmacological blockade and from inhibition driven by circulating mediators.

Current clinical guidelines recommend maintaining platelet counts above 50 billion per liter in active intracranial hemorrhage and above 100 billion per liter around surgery. Those thresholds remain essential, the authors stress, but they address only quantity. A patient whose count is well above both limits may still harbor significant dysfunction at the level of the ADP/P2Y12 or arachidonic acid/cyclooxygenase-1 receptor pathways. The authors also warn against two opposite errors: equating thrombocytopenia with platelet failure, and treating any detected dysfunction as an automatic indication for transfusion. Their framework rests on three clinical questions: which phenotype is present, is it clinically meaningful, and can correcting it actually improve outcomes?

Detecting these phenotypes requires functional testing, and here the landscape is complicated. Standard coagulation tests, including prothrombin time, international normalized ratio, and fibrinogen measurement, are essentially blind to platelet function. Viscoelastic assays such as thromboelastography and rotational thromboelastometry assess whole-blood clot kinetics and strength, and platelet mapping modules add agonist-specific response data. Other platforms, including Multiplate, VerifyNow, and light transmission aggregometry, measure different biological parameters and cannot be directly compared with one another. Cross-platform equivalence in traumatic brain injury has not been established, and the most frequently cited working thresholds, ADP or arachidonic acid inhibition greater than 60 percent on thromboelastography with platelet mapping, were never prospectively validated. They represent observational approximations, not clinical standards, and no universally accepted intervention cutoffs exist for any platform.

The therapeutic evidence is strikingly discordant, and the authors argue that the discordance follows a pattern rather than being random. On the positive side, one retrospective series found that goal-directed platelet transfusion guided by platelet mapping in severe traumatic brain injury was associated with lower mortality, and a platelet mapping algorithm reduced transfusion exposure without apparent harm in patients exposed to antiplatelet drugs. Against this, multiple studies found no benefit and potential harm from empirical platelet transfusion or desmopressin in less severely injured populations or when treatment was not guided by functional testing. The positive studies were conducted in severe injury with documented profound dysfunction and function-guided decisions; the negative studies applied empirical treatment in milder populations. The lesson, the authors conclude, is that intervention should be phenotype-guided and risk-stratified, not routine and empirical.

The risks of getting this wrong are not trivial. Platelet transfusion carries the danger of transfusion-associated circulatory overload, transfusion-related acute lung injury, alloimmunization, and prothrombotic complications, while desmopressin, typically dosed at 0.3 to 0.4 micrograms per kilogram intravenously in structured protocols, can cause hyponatremia, fluid retention, and thrombosis. The authors frame their recommendation through the lens of patient blood management: the question is not whether platelets are good or bad, but whether a clinically relevant, modifiable phenotype exists in which intervention is likely to change meaningful outcomes. They propose a five-category taxonomy matching platelet-related phenotypes to clinical context, dominant mechanism, and therapeutic implication, while candidly noting that this construct is expert-synthesized and has not been prospectively validated as a diagnostic classification system.

The practical approach they sketch is deliberately cautious. Platelet function testing is most defensible in moderate-to-severe injury, traumatic intracranial hemorrhage, radiological progression, planned neurosurgery or invasive neuromonitoring, known preinjury antiplatelet exposure, systemic polytrauma with coagulopathy, or unexplained bleeding despite a normal count. When function is preserved, empirical reversal should generally be avoided. When dysfunction is documented in high-risk patients requiring surgery or invasive monitoring, desmopressin or platelet transfusion may be considered according to phenotype, antiplatelet exposure, count, and procedural urgency, with post-intervention reassessment by clinical status, imaging, and repeat functional testing. Centers without access to viscoelastic platforms can fall back on clinical risk stratification using the Glasgow Coma Scale, lesion subtype, antiplatelet exposure, and procedural urgency, consistent with American College of Surgeons guidance. In emergent surgical scenarios, urgency simply overrides testing; in nonemergent settings, a 30-to-60-minute window permits targeted hemostatic preparation.

The authors are explicit about the limits of their case. Most clinical evidence is observational, retrospective, or single-center; interassay discordance remains a fundamental barrier; dysfunction rarely occurs in isolation and overlaps with fibrinogen abnormalities, acidosis, hypothermia, hypocalcemia, and hemodilution; the dynamic evolution of dysfunction over the first 72 hours is poorly characterized; and findings from moderate-to-severe cohorts cannot be extrapolated to mild injury. Many studies report laboratory correction without demonstrating improved patient outcomes. What they call for is a new generation of prospective, multicenter trials to determine which assay best identifies clinically meaningful dysfunction, which threshold predicts hemorrhagic progression, and whether phenotype-guided correction improves neurological outcomes rather than merely normalizing laboratory values. In neurocritical care, they write, what is hidden beyond the platelet count may be clinically decisive, and the next step is not simply to transfuse more platelets but to understand which platelet phenotype matters, when it matters, and how it can be safely corrected.

Subject of Research: Platelet dysfunction as a hemostatic phenotype in traumatic brain injury coagulopathy

Article Title: Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype

Article References: Quintana Diaz, M., & Godoy, D. A. (2026). Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype. Neurocritical Care. https://doi.org/10.1007/s12028-026-02670-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02670-5

Keywords: traumatic brain injury, platelet dysfunction, coagulopathy, hemostatic phenotype, thromboelastography, platelet mapping, platelet transfusion, desmopressin, intracranial hemorrhage, neurocritical care, patient blood management, P2Y12 pathway

The stakes of this question are enormous. Antithrombotic drugs, including anticoagulants and antiplatelet agents, are prescribed to millions of people for atrial fibrillation, venous thromboembolism, and cardiovascular disease, and they dramatically increase the risk and severity of intracranial hemorrhage. Compared with patients who bleed while not taking these medications, those on antithrombotics face higher rates of hematoma expansion, worse functional outcomes, and greater mortality. Hematoma expansion is the central villain in this story: every additional milliliter of blood within the brain parenchyma carries roughly a five percent increased risk of death or dependency, and approximately a third of patients who present within six hours of symptom onset will experience significant growth of their hemorrhage. Rapid reversal of anticoagulation is therefore one of the most consequential decisions in emergency neurology.

The guideline panel, an interdisciplinary task force of ten specialists spanning neurocritical care, trauma surgery, hematology, nursing, and pharmacy, framed five clinical questions using the Population, Intervention, Comparator, Outcome framework. Three questions updated prior recommendations while two were entirely new. The panelists independently rated outcomes by importance, elevating mortality, functional outcome, and thrombosis to critical status, and applied the Grading of Recommendations, Assessment, Development, and Evaluation methodology to synthesize evidence from randomized trials and observational cohorts. Notably, the panel included a public member recruited through the Anticoagulation Forum to represent the patient and family perspective, and all members were vetted for conflicts of interest before voting.

The most consequential recommendation concerns the showdown between andexanet alfa and prothrombin complex concentrate. Andexanet alfa is an inactive recombinant decoy form of human factor Xa that sponges up factor Xa inhibitors and restores thrombin generation. It was not commercially available when the 2016 guideline was written, and its subsequent rise was propelled largely by the ANNEXA-4 trial, a single-arm study of 352 patients in which 82 percent achieved excellent or good hemostasis. But the new analysis, drawing on 21 studies encompassing 4,938 patients, tells a more sobering story. The sole randomized trial, ANNEXA-I, compared andexanet alfa against usual care in factor Xa inhibitor-associated intracerebral hemorrhage and found no significant mortality benefit: 27.8 percent of andexanet recipients died versus 25.5 percent of those receiving usual care. Andexanet did improve hemostatic efficacy, with 67 percent achieving the composite hemostasis endpoint compared with 53.1 percent under usual care, and it produced less very large hematoma expansion. Yet hemostasis is a surrogate outcome, and the panel prioritized patient-centered endpoints instead.

What tipped the scales decisively was thrombosis. Meta-analysis revealed a significant increase in thrombotic events with andexanet alfa, with a relative risk of 1.37 overall, and in the spontaneous hemorrhage subgroup the risk nearly doubled at a relative risk of 1.99. These events were predominantly arterial, most commonly acute ischemic strokes identified on neuroimaging, and even small asymptomatic infarcts may erode long-term functional recovery. Andexanet alfa appears prothrombotic through two distinct mechanisms: reversal of anticoagulation itself, and direct inhibition of tissue factor pathway inhibitor. These findings contributed to the United States Food and Drug Administration declining AstraZeneca’s application for full approval, and the manufacturer voluntarily withdrew the drug from the US market as of December 2025, though it remains available internationally. The panel therefore issued a conditional recommendation favoring four-factor prothrombin complex concentrate over andexanet alfa for both spontaneous and traumatic factor Xa inhibitor-associated hemorrhage, the latter based on very low certainty evidence.

The guideline also delivers a nuanced verdict on platelet transfusion, long a reflexive response to bleeding on antiplatelet drugs like aspirin and clopidogrel. For patients with spontaneous intraparenchymal hemorrhage who do not require surgery, the panel recommends against platelet transfusion, a position anchored by the PATCH trial, a high-quality randomized study showing that transfusion offered no benefit in mortality, functional outcome, or thrombosis, and in fact was associated with worse functional outcomes. The picture flips for surgical patients: a single randomized trial from China found that aspirin users undergoing craniotomy for basal ganglia hemorrhage who received perioperative platelet transfusion had lower mortality, reduced postoperative hemorrhage, and better six-month functional outcomes. The panel accordingly suggests platelet transfusion for aspirin-treated patients requiring neurosurgery, while explicitly limiting this recommendation to aspirin because no data exist for P2Y12 inhibitors in this setting. For traumatic intracranial hemorrhage, where ten retrospective studies produced contradictory and confounded results, the panel declined to make any recommendation at all.

Desmopressin, a vasopressin analog that releases factor VIII and von Willebrand factor and may enhance platelet procoagulant activity, fared no better. The 2016 guideline had suggested considering a single dose for antiplatelet-associated hemorrhage, but the new analysis, including the DASH phase 2 feasibility trial and nine observational studies, found no effect on hematoma expansion, mortality, or functional outcome, with all confidence intervals crossing unity. The panel made no recommendation, while emphasizing the urgent need for adequately powered randomized trials of a treatment that remains biologically plausible for a condition with no proven therapy. Similarly, the panel could not issue guidance on whether to reverse anticoagulation in patients with very small intraparenchymal hemorrhages, a genuinely difficult clinical dilemma, since no studies directly address it. The decision hinges on factors such as time from onset to imaging, hemorrhage location, the specific anticoagulant and timing of the last dose, and imaging markers like the CT spot sign that predict expansion.

One genuinely new recommendation embraces technology over therapeutics. Viscoelastic hemostatic assays, including thromboelastography and rotational thromboelastometry, are point-of-care whole blood tests that render real-time coagulation dynamics rather than static snapshots. The panel suggests using these assays to guide treatment of coagulopathy in traumatic intracranial hemorrhage when available, a conditional recommendation resting on very low certainty evidence but supported by a mortality signal in the severe traumatic brain injury subgroup of one randomized trial, with a relative risk of 0.59. Because the tests carry minimal inherent risk compared with medications or transfusions, the panel judged the balance favorable even with sparse data, though it acknowledged that treatment protocols vary widely between centers and that standardized algorithms remain lacking.

The panel was candid about the limitations pervading this literature. Observational studies comparing andexanet with prothrombin complex concentrate are vulnerable to selection bias, since patients assigned to usual care were often treated later, had higher blood pressures, or were perceived as having better prognoses, patterns that could artificially favor andexanet. Formulations of prothrombin complex concentrate differ in factor content, some contain heparin, and none carries a labeled indication for factor Xa inhibitor reversal, while optimal dosing, historically 50 units per kilogram, was never established on robust data. The panel also advised against combining andexanet alfa with prothrombin complex concentrate unless benefit clearly outweighs the prothrombotic risk, and flagged a practical pitfall: patients transferred between hospitals may arrive without documentation of reversal agents already given.

Perhaps the most telling conclusion is what the guideline could not say. Not a single strong recommendation emerged from the entire exercise, a reflection of how thin the evidence remains for one of the most feared complications of modern cardiovascular medicine. The panel laid out a research agenda calling for randomized trials of platelet transfusion in traumatic hemorrhage, adequately powered studies of desmopressin, direct comparisons of reversal versus observation in small hemorrhages, and standardized viscoelastic assay protocols. Until those trials arrive, clinicians now have a clearer, more skeptical map of the territory: favor prothrombin complex concentrate over andexanet, withhold platelets from non-surgical patients, give them to aspirin users heading for the operating room, and let real-time coagulation testing steer trauma resuscitation. In a field where overtreatment has proven as dangerous as undertreatment, knowing what not to do may be the guideline’s most valuable contribution.

Subject of Research: Guideline-based reversal of antithrombotic medications in adults with acute intracranial hemorrhage

Article Title: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine

Article References: Vallejo, M. C., Kennedy, L. S., Dengler, B., Barthol, C., Belley-Cote, E. P., Burns, J. D., Chau, V. K., Cordonnier, C., Cuker, A., Honarmand, K., Mahmoud, S. H., Wilcox, M. E., & Kumar, M. A. (2026). Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine. Neurocritical Care. https://doi.org/10.1007/s12028-026-02601-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02601-4

Keywords: intracranial hemorrhage, antithrombotic reversal, andexanet alfa, prothrombin complex concentrate, platelet transfusion, desmopressin, factor Xa inhibitors, antiplatelet agents, viscoelastic hemostatic assays, GRADE methodology, neurocritical care, clinical guideline

The research, led by Bailey B. Zeiler and Robert D. Christensen of the University of Utah, together with colleagues at Intermountain Health, ARUP Laboratories, and Boston Children’s Hospital, set out to answer a deceptively simple question: what is actually normal for a newborn’s platelet count? Rather than relying on the conventional adult-derived figure, the team turned to the international hematologic consensus definition of cytopenia, which classifies a blood count as abnormally low only when it falls below the 2.5th percentile of an appropriate comparison population. Applying that standard to neonates required accurate reference intervals for newborn platelet counts, which historically have been difficult to establish.

The key methodological innovation was the refineR algorithm, a statistical tool developed to estimate reference intervals from large volumes of routine clinical laboratory data. Traditional approaches to defining reference intervals require recruiting large numbers of demonstrably healthy individuals and measuring them under standardized conditions, an approach that is logistically daunting in neonatology, where ethically obtaining blood samples from healthy newborns is nearly impossible. Indirect methods such as refineR sidestep this problem by mining the enormous datasets that hospitals already generate, mathematically separating the distribution of results from healthy individuals from the skewed contributions of sick patients whose abnormal values pull the tails of the distribution.

RefineR works by modeling the mixture of distributions present in real-world laboratory data, identifying the dominant, presumably healthy subpopulation and estimating its central tendency and spread without requiring manual exclusion of pathological results. The algorithm has been validated for a growing list of laboratory parameters and has been recommended in guidance from the International Federation of Clinical Chemistry and Laboratory Medicine on indirect methods for reference interval determination. The Utah and Boston team had previously used refineR to establish neonatal reference intervals for other hematologic measures, including nucleated red blood cell counts and red cell parameters, and platelets were the natural next target.

The scale of the analysis is what gives the new intervals their statistical power. Drawing on large multihospital clinical databases, the researchers assembled 155,062 neonatal platelet counts. From this dataset they generated reference intervals for the day of birth, stratified by gestational age, and for the first 30 days after birth across all gestational ages. The results were striking. For neonates born at 34 weeks of gestation or later, the lower reference limit, corresponding to the 2.5th percentile, was 119,600 platelets per microliter, with a 95 percent confidence interval of 117,700 to 135,300. For neonates born before 34 weeks, the lower limit was even lower, at 103,000 platelets per microliter, with a confidence interval of 98,700 to 105,600.

Those numbers carry an immediate clinical implication that the authors state plainly: platelet counts in the range of 120,000 to 150,000 per microliter at birth are normal for many newborns. Under the traditional definition, a term infant with a platelet count of 135,000 per microliter would be labeled thrombocytopenic, potentially triggering additional testing, parental anxiety, and in some cases interventions. Under the new evidence-based intervals, that same count sits comfortably within the expected range. The gap between the old and new definitions is not a marginal statistical quibble; it encompasses a substantial band of counts that clinicians encounter every day in nurseries and neonatal intensive care units.

The stakes extend well beyond labeling. Platelet transfusions are among the most common blood products administered to preterm infants, and the thresholds at which transfusion is given have been the subject of intense debate. The landmark PlaNeT-2 randomized trial, published in the New England Journal of Medicine in 2019, found that prophylactic platelet transfusion at a higher threshold of 50,000 per microliter did not reduce major bleeding compared with a lower threshold of 25,000 per microliter in neonates with thrombocytopenia, and follow-up studies have raised concerns about long-term outcomes associated with more liberal transfusion practices. Subsequent work has documented the challenges of implementing restrictive transfusion guidelines in neonatal units, and international clinical practice guidelines from the AABB and the International Collaboration for Transfusion Medicine Guidelines have endorsed more conservative approaches.

Accurate definitions of thrombocytopenia are the foundation on which such transfusion decisions rest. If the diagnostic threshold itself is miscalibrated, then every downstream decision, from the ordering of infectious disease workups to the administration of transfusions, inherits that error. Overdiagnosis of thrombocytopenia can lead to unnecessary transfusions, which carry known risks including transfusion-associated circulatory overload, infection transmission, and, according to some recent research, possible contributions to conditions such as bronchopulmonary dysplasia. Underdiagnosis, conversely, could delay evaluation of infants who genuinely have pathological platelet counts caused by sepsis, necrotizing enterocolitis, alloimmune processes, or congenital syndromes.

The new reference intervals also refine the picture of how platelet counts naturally vary in the earliest days of life. By modeling counts across the first 30 days, the study provides a dynamic view of the expected trajectory, acknowledging that the normal range in a three-day-old preterm infant differs from that of a newborn on the day of birth. Previous efforts, including a well-known 2009 analysis of more than 47,000 patients from the same Intermountain healthcare system, established that neonatal platelet counts vary with gestational age and postnatal age, but the refineR approach allows continuous, statistically robust estimation from routine data rather than relying on manually curated healthy cohorts.

The authors emphasize that the study was a retrospective review of de-identified records, approved by the Intermountain Health Institutional Review Board with a waiver of informed consent, and conducted in accordance with federal human subjects protections. The team reports no competing interests, and the statistical code is available upon request. As neonatal units and clinical laboratories consider adopting the new intervals, the practical effect will likely be a recalibration of what triggers concern: a count that once read as mildly low may now read as normal, reserving the label of thrombocytopenia, and the interventions that follow it, for infants whose platelet counts genuinely fall below the physiological range for their gestational age and postnatal day. In a field where the smallest patients receive the most cautious care, that shift in the denominator of normal could spare thousands of newborns each year from unnecessary labels and the cascade of interventions that labels invite.

Subject of Research: Establishment of evidence-based neonatal platelet reference intervals using the refineR algorithm to redefine thrombocytopenia in newborns

Article Title: Redefining neonatal thrombocytopenia: an evidence-based approach, improved by the refineR algorithm

Article References: Zeiler, B. B., Bahr, T. M., Doyle, K., Henry, E., Carlson, L. C., Davenport, P., Sola-Visner, M. C., Ohls, R. K., & Christensen, R. D. (2026). Redefining neonatal thrombocytopenia: an evidence-based approach, improved by the refineR algorithm. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02888-3

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02888-3

Keywords: neonatal thrombocytopenia, platelet count, refineR algorithm, reference intervals, newborns, preterm infants, platelet transfusion, neonatology, hematology, Journal of Perinatology, gestational age, clinical laboratory data